Highlights Lumosa Therapeutics Co., Ltd.

Equities

6535

TW0006535008

End-of-day quote Taipei Exchange Other stock markets 23:00:00 30/06/2024 BST			5-day change	1st Jan Change
240 ^TWD	+2.13%		+8.60%	+251.39%

05-14	Lumosa Therapeutics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05-14	Lumosa Therapeutics Co., Ltd. Announces the Change of Chairperson	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lumosa Therapeutics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
Lumosa Therapeutics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04-01	CI
Lumosa Therapeutics and CHI Memorial Announce New Study for Acute Stroke	02-02	CI
Lumosa Therapeutics Co., Ltd. Receives Approval to Initiate Phase 2, Multiple-Dose Study of Its LT3001	01-22	CI
Lumosa Therapeutics Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-10	CI
Lumosa Therapeutics Co., Ltd. Approves the Exclusive Licensing Agreement with Gufic Biosciences for LT1001, A Long-Acting Analgesic Injection	11-09	CI
Lumosa Therapeutics Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/08/23	CI
Lumosa Therapeutics Co., Ltd. Approves Formulation Patent for Lumosas Lt3001, A New Drug for Acute Ischemic Stroke	26/07/23	CI
Lumosa Therapeutics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
Lumosa Therapeutics Co., Ltd. Approves Exclusive Licensing Agreement with Pakistan’s AJM Pharma Pvt. Ltd. for LT1001, A Long-Acting Analgesic Injection	23/12/22	CI
Lumosa Therapeutics Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10/11/22	CI
Lumosa Therapeutics Co., Ltd. Approves the Revised Exclusive Licensing Agreement for the Veterinary Analgesic with Skyline Vet Pharma, Inc	09/08/22	CI
Lumosa Therapeutics Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	08/08/22	CI
Lumosa Therapeutics Co., Ltd. Approves the Amendments for the Exclusive Licensing Agreement for the Veterinary Analgesic	31/05/22	CI
Lumosa Therapeutics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	09/05/22	CI
LUMOSA Therapeutics Announces TFDA’s Clearance of Phase 2 IND Application for Multiple-Dose of LT3001 in Patients	24/03/22	CI
Lumosa Therapeutics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	03/03/22	CI
Lumosa Therapeutics Announces US FDA Clearance of IND Application for a Phase 2 Multi-Dose Study of LT3001 in Patients with Acute Ischemic Stroke	09/02/22	CI
Lumosa Therapeutics Co., Ltd. Announces Lt3001 Granted Fast TrackDesignation for the Treatment of Acute Ischemic Stroke Toexpedite the Drug Registration Process with the US FDA	11/01/22	CI
Lumosa Announces the Completion of the Phase 1Clinical Trial on the Pharmacokinetics of Multiple Dosesand the Drug-Drug Interaction for LT3001	06/01/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Lumosa Therapeutics Co., Ltd.

Equities

6535

TW0006535008

Highlights

Filters